Companies › Vaxart
Vaxart: clinical trials, targets and expected readouts
1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
Programs Drug Target Highest phase Conditions Next expected readout VXA-CoV2-3.3 Oral SARS-CoV-2 vaccine (KP.2 strain)
– Phase 2 SARS-CoV2 May 2027
Trials Registry id Drug Phase Conditions Area Expected readout NCT06672055 VXA-CoV2-3.3 Phase 2 SARS-CoV2 Infectious disease May 2027
From the company's SEC filings Cash and short-term investments of $66m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
2026-11-05 · 8-K 2026-10-19 · 8-K 2026-09-14 · 8-K 2026-08-25 · 8-K 2026-08-06 · 8-K Agreements filed with the SEC (item 1.01), last two years 2026-06-26 · collaboration · On June 22, 2026, Vaxart, Inc. (the “Company”) entered into Modification No. 7 (the “Modification”) to the ATI 2025-11-05 · licence with Dynavax Technologies Corporation · Exclusive License and Collaboration Agreement On November 4, 2025, Vaxart, Inc. (“Vaxart” or the “Company”) en 2025-08-06 · collaboration with Human Services. The Company · To the extent required by this Item 1.01, the disclosure set forth under Item 8.01 is hereby incorporated into 2025-04-28 · collaboration · To the extent required by this Item 1.01, the disclosure set forth under Item 8.01 is hereby incorporated into 2025-02-24 · collaboration · To the extent required by this Item 1.01, the disclosure set forth under Item 8.01 is hereby incorporated into 2025-02-10 · collaboration with Drug Administration. The Company · On February 7, 2025, Vaxart, Inc. (the “Company”) entered into Modification No. 5 (the “Modification”) to the
Targets No annotated target.
Companies with the same targets –
Companies built like this Green Cross Osivax Artcline Shanghai HEP Pharmaceutical BiomX
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.
Built from ClinicalTrials.gov, CTIS, FDA, PubMed and OpenAlex, read every week; this page from the landscape of 2026-11-09. Phaseline reads registries; it is not investment or medical advice. Method and sources · Privacy · Contact